|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Virginia Commonwealth University |
|---|---|
| Collaborator: |
National Cancer Institute (NCI) |
| Information provided by: | Virginia Commonwealth University |
| ClinicalTrials.gov Identifier: | NCT00006456 |
Purpose
RATIONALE: Stereotactic radiosurgery delivers x-rays directly to the tumor and may cause less damage to normal tissue.
PURPOSE: Phase II trial to study the effectiveness of stereotactic radiosurgery in treating patients who have liver metastases, lung metastases, or other advanced solid tumors.
| Condition | Intervention | Phase |
|---|---|---|
|
Metastatic Cancer Unspecified Adult Solid Tumor, Protocol Specific |
Radiation: stereotactic radiosurgery |
Phase II |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety Study Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Fractionated Stereotactic Body Radiosurgery for Extracranial Tumors |
| Enrollment: | 26 |
| Study Start Date: | February 1999 |
| Study Completion Date: | November 2004 |
| Primary Completion Date: | November 2004 (Final data collection date for primary outcome measure) |
OBJECTIVES:
OUTLINE: Patients receive fractionated stereotactic body radiosurgery over 30 minutes for 5-10 days for a total of 3 treatments.
Patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 10-25 patients will be accrued within 2-3 years.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed malignancy
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Pulmonary:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Contacts and Locations| United States, Virginia | |
| Massey Cancer Center | |
| Richmond, Virginia, United States, 23298-0058 | |
| Study Chair: | Danny Y. Song, MD | Massey Cancer Center |
More Information
| Responsible Party: | Danny Song, MD, Virginia Commonwealth University/Massey Cancer Center |
| ClinicalTrials.gov Identifier: | NCT00006456 History of Changes |
| Other Study ID Numbers: | CDR0000068151, P30CA016059, MCV-MCC-9812-2C, NCI-V00-1612 |
| Study First Received: | November 6, 2000 |
| Last Updated: | February 23, 2010 |
| Health Authority: | United States: Federal Government |
|
unspecified adult solid tumor, protocol specific lung metastases liver metastases |
|
Neoplasm Metastasis Neoplasms Neoplasms, Second Primary Neoplastic Processes Pathologic Processes |